Medifast (MED) Defended at DA Davidson
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Wall Street ends lower, off record highs, as Treasury yields climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
- HubSpot to cut 7% of workforce in restructuring plan
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- Sportradar to sell Synergy Sports coaching unit for $170M
- Caribou Biosciences to halt CAR-T programs, explore sale
- Rezolve AI (RZLV) Reiterated at Overweight by Cantor Fitzgerald on Positioning as Key Component in E-Commerce Stack
Medifast (MED) Reports In-Line Q3 EPS, Offers Guidance
November 6, 2018 4:13 PM ESTMedifast (NYSE: MED) reported Q3 EPS of $1.14, in-line with the analyst estimate of $1.14. Revenue for the quarter came in at $139.2 million versus the consensus estimate of $125.81 million.
GUIDANCE:
Medifast sees Q4 2018 EPS of $1.15-$1.20, versus the consensus of $1.16. Medifast sees Q4 2018... More



